½ÃÀ庸°í¼­
»óǰÄÚµå
1800799

»êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå º¸°í¼­ : Á¦Ç°, ±â¼ú, °Ë»ç À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Oxidative Stress Assay Market Report by Product, Technology (ELISA, Flow Cytometry, Chromatography, Microscopy, High-Content Screening, Label-Free Detection, and Others), Test Type, End User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 121 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð´Â 2024³â 9¾ï 3,780¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 19¾ï 3,500¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â »çÀÌ 7.96%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ¿¡ ´ëÇÑ ¼ö¿ä´Â ¸¸¼º °Ç°­ »óÅÂÀÇ È®»ê, Áø´Ü ¼Ö·ç¼ÇÀÇ ¹ßÀü, »ý¸í°øÇÐ ¼Ö·ç¼ÇÀÇ È®´ë, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

»êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå µ¿Çâ:

±â¼ú ¹ßÀü

»êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå¿¡¼­´Â ÀÚµ¿È­, ÇÏÀ̽º·çDz ½ºÅ©¸®´×, °í±Þ °ËÃâ Ç÷§Æû µî ºÐ¼® °³Ã´À» À§ÇÑ ±â¼úÀÌ ºü¸£°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ºÐ¼®ÀÇ À¯È¿¼ºÀ» ³ôÀ̰í, ÀÓ»óÀÇ¿Í ¿¬±¸ÀÚµéÀÌ ´Ù¼öÀÇ °Ë»ç¸¦ µ¿½Ã¿¡ ½Ç½ÃÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ¼Óµµ¿Í Á¤È®¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÚµ¿È­¸¦ ÅëÇØ ÀÎÀ§ÀûÀÎ ½Ç¼ö¸¦ ÁÙÀ̰í, ÀÓ»ó ¹× ¿¬±¸¿ë ºÐ¼®ÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í Ȱ¿ëµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ƯÈ÷ ½Å¾à°³¹ß°ú ¸ÂÃãÀÇ·á¿¡ À¯¸®Çϸç, »êÈ­½ºÆ®·¹½º ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Å¼ÓÇϰí Á¤È®ÇÏ°Ô ºÐ¼®ÇÏ´Â °ÍÀº Ç¥Àû Ä¡·áÁ¦ °³¹ß ¹× Áúº´±¸Á¶¸¦ ÆÄ¾ÇÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

¸ÂÃãÇü ÀÇ·á´Â ¸ðµç »ç¶÷À» À§ÇÑ ¸ÂÃãÇü ÀÇ·áÀÇ ¹Ì·¡¸¦ È®ÀåÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ±âȸÀ̸ç, Áúº´ÀÇ Ä¡·á¿Í ¿¹¹æ¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±¹Á¦°³ÀθÂÃãÀÇ·áÄÁ¼Ò½Ã¾ö(ICPerMed)ÀÇ ºñÀü 2030Àº °³ÀÎ ¹× ½Ã¹Î Âü¿©, ÀÇ·á Àü¹®°¡ Âü¿©, °Ç°­ °ü·Ã µ¥ÀÌÅÍ, ÀÇ·á ½Ã½ºÅÛ ³» ±¸Çö, Áö¼Ó°¡´ÉÇÑ °æÁ¦ ¸ðµ¨ °³¹ßÀ̶ó´Â 5°¡Áö ÁÖ¿ä Ãø¸é¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. Áö¼Ó°¡´ÉÇÑ °æÁ¦ ¸ðµ¨À» ÅëÇØ Áø´Ü, Ä¡·á, ¿¹¹æ ¹æ¹ýÀÌ °­È­µÇ°í, »õ·Î¿î ÇコÄÉ¾î °³³äÀ¸·Î ÀÏ¹Ý ½Ã¹ÎÀÇ ÆíÀǼºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â »êÈ­½ºÆ®·¹½º¿Í °ü·ÃµÈ ¸¸¼ºÁúȯÀÇ Ä¡·á¿¡ º¯È­¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å¾à ¿¬±¸°³¹ß È®´ë

ÁÖ¿ä Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀÌ ½É°¢ÇÑ Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ R&D ÀÌ´Ï¼ÅÆ¼ºê¸¦ ºü¸£°Ô È®´ëÇϸ鼭 »êÈ­ ½ºÆ®·¹½º °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CitelineÀÇ Pharma R&D Annual Review 2023¿¡ µû¸£¸é, ÀǾàǰ¿¡ ƯȭµÈ ¿¬±¸°³¹ß Ȱµ¿¿¡ Âü¿©Çϰí Ȱ¹ßÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» º¸À¯ÇÑ Á¦¾à±â¾÷Àº ÃÑ 5,529°³»çÀ̸ç, °³¹ß ÁßÀÎ ÀǾàǰÀº 21,292°³ ÀÌ»ó¿¡ ´ÞÇÕ´Ï´Ù. ¸¹Àº Á¦¾à»ç ¹× ¹ÙÀÌ¿ÀÅØ ±â¾÷µéÀÌ ½Å¾à Èĺ¸¹°ÁúÀÇ ¼¼Æ÷ »êÈ­ ½ºÆ®·¹½º¿¡ ´ëÇÑ È¿°ú¸¦ ÃøÁ¤Çϱâ À§ÇØ ½Å¾à °³¹ß ¹× ¾à¹° °³¹ß¿¡ ÀÖ¾î »êÈ­ ½ºÆ®·¹½º ¾î¼¼À̸¦ ¼öÇàÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû °Ç°­»óÅ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ R&D ºñ¿ëÀÇ ±ÞÁõÀº »êÈ­½ºÆ®·¹½º Å×½ºÆ®ÀÇ ½ÃÀå °³Ã´À» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

POC(Point-of-Care) ¹× ÀçÅà °Ë»ç ŰƮ º¸±Þ È®´ë

ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î °Ç°­ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ÇöÀå Áø·á(POC) ¹× °¡Á¤¿ë ½ºÆ®·¹½º Å×½ºÆ® ŰƮÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç ŰƮ¸¦ »ç¿ëÇÏ¸é º´¿øÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ »êÈ­ ½ºÆ®·¹½º ¼öÁØÀ» Æò°¡ÇÒ ¼ö ÀÖ¾î ¿¹¹æÀû °Ç°­ °ü¸®¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â À£ºù°ú ¼¿ÇÁ Äɾ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½ÉÀÌ ³ô¾ÆÁö´Â °Í°ú ÀÏÄ¡ÇÕ´Ï´Ù. ÈÞ´ë¿ë °Ë»ç ÀåºñÀÇ ¹ßÀü°ú ÇÔ²² ÀÌ·¯ÇÑ Æí¸®ÇÑ °Ë»ç ŰƮÀÇ ½Å·Ú¼º°ú Á¤È®µµ°¡ Áö¼ÓÀûÀ¸·Î Çâ»óµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ »êÈ­ ½ºÆ®·¹½º ¾î¼¼ÀÌ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ½Ã¾à°ú ¼Ò¸ðǰ
  • ±â±â
  • ¼­ºñ½º

Á¦7Àå ½ÃÀå ³»¿ª : ±â¼úº°

  • ELISA(È¿¼Ò¸é¿ªÃøÁ¤¹ý)
  • À¯¼¼Æ÷ ºÐ¼®
  • Å©·Î¸¶Åä±×·¡ÇÇ
  • Çö¹Ì°æ °Ë»ç
  • HCS(High Content Screening)
  • ¹«Ç¥Áö °ËÃâ
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : °Ë»ç À¯Çüº°

  • °£Á¢ ¾î¼¼ÀÌ
    • ÁÖ¿ä Á¾·ù
      • ´Ü¹éÁú ±â¹Ý ¾î¼¼ÀÌ
      • ÁöÁú ±â¹Ý ¾î¼¼ÀÌ
      • ÇÙ»ê ±â¹Ý ¾î¼¼ÀÌ
  • Ç×»êÈ­´É ¾î¼¼ÀÌ
    • ÁÖ¿ä Á¾·ù
      • ±Û·çŸġ¿Â ¾î¼¼ÀÌ
      • ¾Æ½ºÄÚ¸£ºê»ê ¾î¼¼ÀÌ
      • ¼¼Æ÷ ±â¹Ý ¿ÜÀμºÇ×»êÈ­¹°Áú ¾î¼¼ÀÌ
  • È¿¼Ò ±â¹Ý ¾î¼¼ÀÌ
  • Ȱ¼º »ê¼ÒÁ¾¿¡ ±â¹ÝÇÑ ¾î¼¼ÀÌ

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾à ¾÷°è
  • Á¶»ç±â°ü
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abcam PLC
    • AMS Biotechnology(Europe) Ltd.
    • Biovision Inc.(Boai NKY Medical Holdings Ltd.)
    • Cell Biolabs Inc.
    • Enzo Biochem Inc.
    • ImmunoChemistry Technologies LLC
    • Merck KGaA
    • Oxford Biomedical Research
    • Promega Corporation
    • Qiagen N.V.
    • Thermo Fisher Scientific Inc.
KSM

The global oxidative stress assay market size reached USD 937.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,935.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.96% during 2025-2033. The demand for oxidative stress assays is driven by the increasing prevalence of chronic health conditions, advancements in diagnostic solutions, expansion of biotechnology solutions, and rising awareness about preventive healthcare.

Oxidative Stress Assay Market Trends:

Technological Advancements

The oxidative stress assay market is experiencing rapid advancements in technologies for assay development, such as automation, high-throughput screening, and more advanced detection platforms. These advancements enhance the effectiveness of assays, thereby enabling clinicians and researchers to conduct numerous tests simultaneously, which improves speed and accuracy. Automation helps reduce human errors, which makes assays more dependable and accessible for clinical and research applications. These advancements are advantageous particularly in drug discovery and personalized medicine, where rapid analysis and high accuracy of oxidative stress biomarkers are critical for the development of targeted therapies and identification of disease structures.

Increasing Demand for Personalized Medicine

Personalized medicine exhibits a noteworthy opportunity to augment the future of individualized healthcare for everyone, which is projected to revolutionize disease treatment and prevention. The Vision 2030 by International Consortium for Personalized Medicine (ICPerMed) focuses on five key aspects: individual and public engagement, inclusion of healthcare professionals, health-related data, implementation within healthcare systems, and the development of sustainable economic models. The sustainable economic models enable enhanced diagnostic, therapy, and preventive methods as new healthcare concepts for the advantage of the public. This trend is projected to transform the treatment of chronic ailments related to oxidative stress.

Expansion of Research in Drug Discovery and Development

The rapid growth in R&D initiatives by key pharma and biotechnology companies for developing innovative treatment for critical diseases is projected to propel the demand for oxidative stress tests. According to the Pharma R&D Annual Review 2023 by Citeline, the total number of pharmaceutical companies involved in pharma-specific R&D activities with active pipelines were around 5,529, with over 21,292 pharmaceutical drugs under development. Numerous pharmaceutical and biotechnology companies are implementing oxidative stress assays in drug discovery and development for gauging the effects of new drug candidates on cellular oxidative stress. An upsurge in R&D expenditure for developing novel therapeutic drugs for targeted health conditions is anticipated to increase the market uptake for oxidative stress tests.

Growing Adoption of Point-of-Care and At-Home Testing Kits

The growing popularity of point-of-care (POC) and at-home stress test kits is becoming ever more prevalent due to the proliferating demand for portable and easy-to-use health monitoring solutions. These test kits enable individuals to evaluate the levels of oxidative stress without the need for a hospital visit, which also encourages preventive health management. This trend aligns with the rising consumer interest in wellness and self-care. As the technology that drives portable testing devices witnesses advancements, the reliability and preciseness of these convenient kits continue to augment, driving the market growth further.

Oxidative Stress Assay Market Segmentation:

Breakup by Product:

  • Reagents and Consumables
  • Instruments
  • Services

Reagents and consumables segment accounts for the majority of the market share

Reagents and consumables form the mainstay of oxidative stress assay operations. These products are used for detecting a number of metabolites in pathways of oxidative stress and cellular damage, including reactive oxygen species and nitric oxide. The segment growth is driven by factors such as rapid surge in research initiatives for drug discovery and development, advancements in assay operations, and the increasing demand of reagents in detection of biomarkers.

Breakup by Technology:

  • ELISA (Enzyme-Linked Immunosorbent Assay)
  • Flow Cytometry
  • Chromatography
  • Microscopy
  • High-Content Screening
  • Label-Free Detection
  • Others

ELISA holds the largest share of the industry

ELISA is highly sensitive assay for detecting a varied range of biomarkers. The increasing availability of ELISA for status markers in oxidative stress tests enables the assessment of several pathophysiologic conditions, such as diabetes. It helps identify and measure proteins and antigens in a given sample. ELISA finds applications across quality control, research, and diagnostics.

Breakup by Test Type:

  • Indirect Assays
    • Protein-Based Assays
    • Lipid-Based Assays
    • Nucleic Acid-Based Assays
  • Antioxidant Capacity Assays
    • Glutathione Assays
    • Ascorbic Acid Assays
    • Cell-Based Exogenous Antioxidant Assays
  • Enzyme-Based Assays
  • Reactive Oxygen Species-Based Assays

Indirect assays represented the leading market segment

The indirect assays segment dominates the global market owing to the versatility of these assays in conducting the overall evaluation of oxidative stress. Indirect assays are suitable for analyzing low-expressed proteins based on the signal amplification by the secondary antibody. Secondary antibodies are comparatively inexpensive than primary antibodies used in direct assays and can be implemented to detect various primary antibodies.

Breakup by End User:

  • Pharmaceutical Industry
  • Research Institutes
  • Others

Pharmaceutical industry exhibits a clear dominance in the market

The pharmaceutical companies in the market deploy oxidative stress assays for identifying and developing prospective targets for therapeutic treatment, evaluating the effectiveness of drug candidates in alleviating oxidative stress, and tracking the status of oxidative stress among patients undergoing treatment.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest oxidative stress assay market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for oxidative stress assay.

The North America market holds a significant market share owing to increasing R&D funding and supportive government initiatives in healthcare sector. The presence of numerous pharmaceutical & biotechnology companies and research institutes developing novel therapies for diverse range of diseases and enhanced healthcare infrastructure is supporting the market expansion in the region.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the oxidative stress assay industry include Abcam PLC, AMS Biotechnology (Europe) Ltd., Biovision Inc. (Boai NKY Medical Holdings Ltd.), Cell Biolabs Inc., Enzo Biochem Inc., ImmunoChemistry Technologies LLC, Merck KGaA, Oxford Biomedical Research, Promega Corporation, Qiagen N.V., and Thermo Fisher Scientific Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the oxidative stress assay market are increasingly emphasizing strategic business initiatives including product launch, partnerships, mergers, and acquisitions to strengthen their foothold in the market. Companies including Abcam, Thermo Fisher Scientific, and Merck are involved in the development of advanced, high-throughput oxidative stress assay kits for quicker and more precise outcomes. Business tie-ups with pharmaceutical companies and research institutions enable these players to expand their application areas in drug discovery and personalized medicine. Furthermore, some of the key companies are investing in digital platforms and automation for enhancing the effectiveness and scalability of oxidative stress assays, while also monitoring the potential of emerging markets to widen their customer base and expand the market reach across different regions.

Key Questions Answered in This Report:

  • How has the global oxidative stress assay market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global oxidative stress assay market?
  • What is the impact of each driver, restraint, and opportunity on the global oxidative stress assay market?
  • What are the key regional markets?
  • Which countries represent the most attractive oxidative stress assay market?
  • What is the breakup of the market based on product?
  • Which is the most attractive product in the oxidative stress assay market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the oxidative stress assay market?
  • What is the breakup of the market based on test type?
  • Which is the most attractive test type in the oxidative stress assay market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the oxidative stress assay market?
  • What is the breakup of the market based on region?
  • Which is the most attractive region in the oxidative stress assay market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global oxidative stress assay market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oxidative Stress Assay Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Reagents and Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 ELISA (Enzyme-Linked Immunosorbent Assay)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Flow Cytometry
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chromatography
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Microscopy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 High-Content Screening
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Label-Free Detection
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Indirect Assays
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Protein-Based Assays
      • 8.1.2.2 Lipid-Based Assays
      • 8.1.2.3 Nucleic Acid-Based Assays
    • 8.1.3 Market Forecast
  • 8.2 Antioxidant Capacity Assays
    • 8.2.1 Market Trends
    • 8.2.2 Major Types
      • 8.2.2.1 Glutathione Assays
      • 8.2.2.2 Ascorbic Acid Assays
      • 8.2.2.3 Cell-Based Exogenous Antioxidant Assays
    • 8.2.3 Market Forecast
  • 8.3 Enzyme-Based Assays
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Reactive Oxygen Species-Based Assays
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Industry
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abcam PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AMS Biotechnology (Europe) Ltd.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Biovision Inc. (Boai NKY Medical Holdings Ltd.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Cell Biolabs Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Enzo Biochem Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 ImmunoChemistry Technologies LLC
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Oxford Biomedical Research
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Promega Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Qiagen N.V.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦